Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 15, 2010. The report serves as a legal update regarding significant litigation settlements and provisions expected to be recorded in the second quarter of 2010.
Key Financial Metrics
The filing details a specific legal charge rather than comprehensive financial statements. Key figures include:
- Total Legal Charge (Q2 2010): £1.57 billion ($2.36 billion).
- After-Tax Cost: £1.35 billion.
- Cidra Manufacturing Settlement: £500 million ($750 million) agreed in principle with the US Department of Justice.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes and Legal Resolutions
The primary material change is the recognition of a substantial legal charge to resolve long-standing cases. Specific resolutions include:
- Cidra, Puerto Rico: Agreement in principle reached to settle the US Government investigation into the former manufacturing site.
- Paxil (paroxetine): Anti-trust litigation with Apotex fully resolved; the vast majority of product liability cases settled.
- Avandia (rosiglitazone): The substantial majority of product liability cases settled.
- Outstanding Matters: The charge includes provisioning for settled cases and estimates for outstanding cases received for Paxil and Avandia.
Outlook, Risks, and Management Commentary
Management, represented by General Counsel Dan Troy, stated that the charge reflects ongoing efforts to resolve a substantial proportion of outstanding litigation, aiming to reduce financial uncertainty and risk for shareholders. The company continues to work on an investigation by the US Attorney's Office for the District of Colorado regarding sales and promotional practices.
Risks and Contingencies:
- Ultimate liability may vary from the amounts provided depending on litigation outcomes and settlement negotiations.
- There is no assurance that losses will not exceed the reported provisions by a material amount.
- Forward-looking statements are subject to risks described in the 2009 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the final execution of the definitive agreement for the £500 million Cidra settlement.
- Monitor the status of the ongoing US Attorney's Office investigation into sales and promotional practices in Colorado.
- Review the impact of the £1.35 billion after-tax charge on the full-year 2010 earnings guidance.
- Assess the confidentiality terms of the Paxil and Avandia settlements to understand potential future liabilities.